A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Svetomir N. Markovic, Susan M. Geyer, Fitzroy Dawkins, William Sharfman, Mark Albertini, William Maples, Paula M. Fracasso, Tom Fitch, Patricia LoRusso, Alex A. Adjei, Charles Erlichman

Research output: Contribution to journalArticle

123 Scopus citations

Abstract

BACKGROUND. Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma. METHODS. Patients with metastatic melanoma and adequate hematologic, renal, and hepatic function were treated with bortezomib (a 1.5-mg/m2 intravenous bolus twice weekly for 2 of every 3 weeks). Eligible patients were age a 18 years with an Eastern Cooperative Oncology Group performance status of 0-1. The primary goal of the current study was to evaluate the: 18-week disease progression-free survival rate and tolerability of bortezomib in these patients. RESULTS. The current study was intended to treat 45 patients. It was closed at the planned interim analysis due to early evidence of insufficient clinical efficacy. Twenty-seven patients with a median age of 56 years (range, 32-77 years) were accrued. There were no major clinical responses to treatment. Only 6 patients (22%) achieved stable disease. Of these 6 patients, 4 were still stable after 4 cycles of treatment, but were removed from the study due 1:0 toxicity. The median time to disease progression was 1.5 months (95% confidence interval [95% CI]. 1.4-1.6) with a median overall survival of 14.5 months (95% CI, 9-22). Having failed bortezomib, most patients proceeded to other clinical trials. Twenty-six patients were evaluable for toxicity. One patient was removed from the study for other reasons and could not return for the cycle evaluation and thus was never evaluated. Of the 26 patients, no Grade 4/5 treatment-related toxicities (using the National Cancer Institute Common Toxicity Criteria [version 2.0]) were reported. Eleven patients (42%) had Grade 3 toxicities (believed to be at least possibly related to treatment), including sensory neuropathy, thrombocytopenia, constipation, fatigue, ileus, abdominal pain, and infection without neutropenia. The median number of treatment cycles patients received was two (range, one to six treatment cycles). Two patients (7%) had 1 dose delay and 6 patients (22%) had dose reductions during 1 treatment cycle due to adverse events. CONCLUSIONS. Single-agent bortezomib, administered twice weekly × 2 weeks, every 3 weeks at a dose of 1.5 mg/m2, was not found to be effective in the treatment of patients with metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)2584-2589
Number of pages6
JournalCancer
Volume103
Issue number12
DOIs
StatePublished - Jun 15 2005

Keywords

  • Bortezomib
  • General
  • Metastatic malignant melanoma
  • Proteosome inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of bortezomib in the treatment of metastatic malignant melanoma'. Together they form a unique fingerprint.

  • Cite this

    Markovic, S. N., Geyer, S. M., Dawkins, F., Sharfman, W., Albertini, M., Maples, W., Fracasso, P. M., Fitch, T., LoRusso, P., Adjei, A. A., & Erlichman, C. (2005). A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer, 103(12), 2584-2589. https://doi.org/10.1002/cncr.21108